ACE inhibitor use not associated with materially altered risk of cataract

  • Becker C & al.
  • Br J Ophthalmol
  • 7 Feb 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This large observational study suggests that exposure to angiotensin-converting enzyme inhibitors (ACEIs) is not associated with an altered risk for cataract.

Why this matters

  • ACEIs showed beneficial effects on cataract development in experimental studies which stand in contrast to the results of a previous observational study, which reported an increased risk for cataract with ACEIs use.
  • To date, there is very little evidence to prove that ACEIs use is associated with the risk of cataract.

Study design

  • This case-control study evaluated 206,931 cataract cases (age ≥40 years) and equal numbers of matched controls using data from the UK-based Clinical Practice Research Datalink.
  • The number of prescriptions for ACEI and other antihypertensive drugs were assessed and the use of single ACEI substances was explored.
  • Funding: None disclosed.

Key results

  • Use of ACEI was not associated with increased risk for cataract compared with non-use in the analysis for sequential or concomitant use (adjusted OR [aOR], 1.06; 95% CI, 1.04-1.08).
  • Risk of cataract did not increase with other antihypertensive drug classes:
    • calcium channel blocker (OR, 1.10; 95% CI, 1.08-1.11),
    • beta-blocker (OR, 1.07; 95% CI, 1.05-1.09),
    • angiotensin receptor blocker (OR, 1.12; 95% CI, 1.09-1.15).
  • In the analysis of exclusive use, ACEI users were not at increased risk for cataract compared with non-users of any antihypertensive drugs (aOR 1.13; 95% CI, 1.09-1.16).

Limitations

  • Possibility of some controls having early undiagnosed cataract during the study period.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit